Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
How is the Recombinant DNA Technology Market size predicted to change over the forecast window of 2026–2035?
The recombinant dna technology market size has experienced robust growth recently. It is projected to expand from $913.42 billion in 2025 to $998.83 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 9.4%. The factors contributing to this historical growth include the expansion of molecular biology research, the increasing incidence of chronic diseases, advancements in biologics development, a rise in academic and government research funding, and the early commercialization of recombinant therapies.
The recombinant dna technology market size is projected to experience robust expansion over the coming years. This market is anticipated to reach $1414.92 billion by 2030, achieving a compound annual growth rate (CAGR) of 9.1%. Factors driving this growth during the forecast period include greater investments in gene therapy development, a growing need for personalized medicine, the broadening scope of CRISPR-based applications, an intensified focus on sustainable bioproduction, and heightened collaboration between academic institutions and industrial sectors. Key trends expected over the forecast horizon involve the increasing uptake of gene editing platforms, an uptick in the development of recombinant vaccines, wider application of advanced expression systems, an expanding range of cell and gene therapy pipelines, and a stronger emphasis on scalable biomanufacturing processes.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8233&type=smp
Which Drivers Are Contributing To The Expansion Of The Recombinant DNA Technology Market?
The expanding cultivation of genetically engineered crops is anticipated to fuel the future expansion of the recombinant DNA technology market. Genetically modified crops are plants whose genetic composition has been deliberately modified through biotechnological methods. Recombinant DNA (rDNA) technology finds application in genetically modified (GM) crops through a process that involves isolating genes for desired characteristics, creating recombinant DNA, inserting it into recipient crop cells, choosing and examining for proper integration, growing transgenic plants, evaluating trait manifestation, performing field tests, securing regulatory permission, and finally launching crops with enhanced qualities. For example, data from December 2023 by the United States Department of Agriculture, a US-based government body, shows that Canada cultivated 11.7 million hectares of genetically engineered (GE) crops, predominantly canola, soybeans, and corn. This figure indicates a 4% rise compared to 2022, primarily due to the increased acreage dedicated to canola cultivation. Consequently, the growing advancement of genetically modified crops is stimulating the expansion of the recombinant DNA technology market.
What Segment Categories Are Covered In The Recombinant DNA Technology Market?
The recombinant dna technology market covered in this report is segmented –
1) By Product Type: Recombinant Protein Drugs, Vaccines, Genetically Modified Crops, Expression Systems, Cell And Gene Therapy, Gene Editing
2) By Component Type: Expression System, Cloning Vector
3) By Application Type: Food And Agriculture, Health And Disease, Environment, Other Application Types
4) By End-Use Type: Biotechnology And Pharmaceutical Companies, Academic And Government Research Institutes, Other End-Use Types
Subsegments:
1) By Recombinant Protein Drugs: Hormones, Growth Factors
2) By Vaccines: Recombinant Viral Vaccines, Recombinant Bacterial Vaccines, Subunit Vaccines
3) By Genetically Modified Crops: Herbicide-Tolerant Crops, Insect-Resistant Crops, Nutritionally Enhanced Crop
4) By Expression Systems: Bacterial Expression Systems, Yeast Expression Systems, Mammalian Expression Systems
5) By Cell And Gene Therapy: Cell-Based Therapies, Gene Replacement Therapies, CAR T-Cell Therapies
6) By Gene Editing: CRISPR Or Cas9 Technologies, TALENs (Transcription Activator-Like Effector Nucleases), ZFNs (Zinc Finger Nucleases)
How Are Emerging Trends Affecting The Progression Of The Recombinant DNA Technology Market?
Major companies in the recombinant DNA technology market are focusing on incorporating advanced gene-editing techniques, such as clustered regularly interspaced short palindromic repeats (CRISPR)-based recombinant DNA engineering, to enhance precision, therapeutic efficacy, and targeted genome modification. This CRISPR-based recombinant DNA engineering is a molecular technique that utilizes a guide RNA and the Cas9 enzyme to locate and cut specific DNA sequences, enabling capabilities like targeted gene correction, controlled DNA insertion, and efficient genomic modification. For instance, in December 2023, Vertex Pharmaceuticals, a US-based biotechnology company, along with CRISPR Therapeutics, a Switzerland-based gene-editing biotechnology company, obtained approval from the US Food and Drug Administration for Casgevy. Casgevy is a CRISPR-enabled recombinant DNA therapy developed for treating sickle cell disease and transfusion-dependent beta thalassemia through editing a patient’s own stem cells to boost fetal hemoglobin production. Casgevy is characterized by targeted DNA cleavage, high-fidelity gene modification, and ex vivo cell processing. Casgevy improves treatment outcomes by enabling durable gene correction, reducing reliance on conventional treatments, and supporting long-term clinical benefits.
Which Key Market Players Are Investing In Expansion And Innovation Within The Recombinant DNA Technology Market?
Major companies operating in the recombinant dna technology market are Profacgen BioTech Corp, Amgen Inc, Novartis International AG, GenScript Biotech Corporation, Pfizer Inc, Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A, Merck & Co. Inc, Biogen Inc, GlaxoSmithKline PLC, New England Biolabs Inc, Bayer CropScience, F. Hoffmann-La Roche Ltd, Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Vertex Pharmaceuticals Incorporated, CRISPR Therapeutics AG, Editas Medicine Inc, bluebird bio Inc, Lonza Group AG, Horizon Discovery Group PLC, Sarepta Therapeutics Inc, Sangamo Therapeutics Inc
Access The Complete Report For Deeper Market Insights:
https://www.thebusinessresearchcompany.com/report/recombinant-dna-technology-global-market-report
Which Regions Are Projected To Dominate The Recombinant DNA Technology Market In The Coming Years?
North America was the largest region in the recombinant DNA technology market share in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the recombinant dna technology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Recombinant DNA Technology Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=8233&type=smp
Browse Through More Reports Similar to the Global Recombinant DNA Technology Market 2026, By The Business Research Company
Plasmid Dna Manufacturing Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/plasmid-dna-manufacturing-global-market-report
Gene Delivery Technologies Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/gene-delivery-technologies-global-market-report
Dna Digital Data Storage Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/dna-digital-data-storage-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company